Tyrvaya® (varenicline solution) Nasal Spray is indicated for the treatment of the signs and symptoms of dry eye disease.
The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation.
Click here for full Prescribing Information
This site is intended for Healthcare Professionals practicing in the United States.
© 2024 Viatris Inc. and/or its affiliates. All rights reserved.
VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company.
Oyster Point®, the Oyster Point logo, Tyrvaya®, the Tyrvaya logo are trademarks of Oyster Point Pharma, Inc., a Viatris company, in the United States and certain jurisdictions.
US-TYR-2024-00001 04/2024
This website uses cookies and other technologies to personalize content and to show you more personalized ads
(for example, Google Ads and Facebook) on this and other websites, as well as provide you with social media
features on this website (such as, Facebook, Twitter, LinkedIn).
...[read more]
By clicking “Accept” you understand that you are directing Medforce to
disclose your personal information, including internet tracking data
(like cookies and the IP address you used to access this website), to these third parties
for the purposes stated above.
You can still use this website if you do not click “Accept,” but your experience may be different.
For more information, including a list of the categories
of third parties to whom we disclose your personal information, please refer to our
Privacy Policy
or for additional options please check your browser’s settings.
[read less]